Human papillomavirus vaccination in males

Gynecologic Oncology

Volumn 107, Issue 2 SUPPL., 2007, Pages

  Giuliano, Anna R ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Genital warts; HPV infection; Male

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ARTICLE; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; DRUG USE; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MEN'S HEALTH; MORBIDITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; VACCINATION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; CHILD; CONDYLOMATA ACUMINATA; COST OF ILLNESS; FEMALE; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; SEXUAL BEHAVIOR; VACCINATION;

EID: 35248860717     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.07.075     Document Type: Article

References (23)

1. Lacey C.J.N. Therapy for genital human papillomavirus-related disease. J. Clin. Virol. 32S (2005) S82-S90
2. Weinstock H., Berman S., and Cates W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect. Sex. Reprod. Health 86 1 (2004) 6-10
3. Greer C.E., Wheeler C.M., Ladber M.B., Beutner K., Coyne M.Y., Liang H., et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J. Clin. Microbiol. 33 8 (1995) 2058-2063
4. Pascual A., Pariente M., Godinez J.M., Sánchez-Prieto R., Atienzar M., Segura M., et al. High prevalence of human papillomavirus 16 in penile carcinoma. Histol. Histopathol. 22 (2007) 177-183
5. Dunne E.F., Nielson C.M., Stome K.M., Markowitz L.E., and Giuliano A.R. Prevalence of HPV infection among men: a systematic review of the literature. J. Infect. Dis. 194 (2006) 1044-1057
6. Nielson C.M., Flores R., Harris R.B., Abrahamsen M., Papenfuss M.R., Dunne E.F., et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol. Biomark. Prev. 16 6 (2007) 1107-1114
7. Campion M.J., Singer A., Clarkson P.K., and Mc Cance D.J. Increased risk of cervical neoplasia in consorts of men with penile condylomata acuminate. Lancet 1 (1985) 943-946
8. Lacey C.J.N., Lowndes C.M., and Shah K.V. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24 S3 (2006) 35-41
9. Chesson H.W., Blandford J.M., Gift T.L., Tao G., and Irwin K.L. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect. Sex. Reprod. Health 36 1 (2004) 11-19
10. Insinga R.P., Dasbach E.J., and Myers E.R. The health and economic burden of genital warts in a set of private health plans in the United States. Clin. Infect. Dis. 36 11 (2003) 1397-1403
11. Gardasil®. Prescribing information. 2007. Merck & Co., Inc., Whitehouse Station, NJ 08889, USA.
12. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356 19 (2007) 1915-1927
13. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356 19 (2007) 1928-1943
14. Agarwal S.S., Sehgal A., Sardana S., Kumar A., and Luthra U.K. Role of male behavior in cervical carcinogenesis among women with one lifetime sexual partner. Cancer 72 (1993) 1666-1669
15. Buckley J.D., Harris R.W., Doll R., Vessey M.P., and Williams PT. Case-control study of the husbands of women with dysplasia or carcinoma of the cervix uteri. Lancet 2 (1981) 1010-1015
16. Thomas D.B., Ray R.M., Pardthaisong T., Chutivongse S., Koetsawang S., Silpisornkosol S., et al. Prostitution, condom use, and invasive squamous cell cervical cancer in Thailand. Am. J. Epidemiol. 143 (1996) 779-786
17. Zunzunegui M.V., King M.-C., Coria C.F., and Charlet J. Male influences on cervical cancer risk. Am. J. Epidemiol. 123 (1986) 302-307
18. Garnett G.P. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J. Infect. Dis. 191 Suppl. 1 (2005) S97-S106
19. Elbasha E.H., Dasbach E.J., and Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg. Infect. Dis. 13 1 (2007) 28-41
20. May J. HPV vaccination - a paradigm shift in public health. Aust. Fam. Physician 36 3 (2007) 106-111
21. Dempsey A.F., Koutsky L.A., and Golden M. Potential impact of human papillomavirus vaccines on public STD clinic workloads and on opportunities to diagnose and treat other sexually transmitted diseases. Sex. Transm. Dis. 34 7 (2007) 503-507 [July]
22. Vyse A.J., Gay N.J., White J.M., Ramsay M.E., Brown D.W.G., Cohen B.J., et al. Evolution of surveillance of measles, mumps, and rubella in England and Wales: providing the platform for evidence-based vaccination policy. Epidemiol. Rev. 24 (2002) 125-136
23. Tookey P.A., and Peckham C.S. Surveillance of congenital rubella in Great Britain, 1971-96. Br. Med. J. 318 (1999) 769-770